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Abstract
Background: Anti-vascular endothelial growth factor (VEGF) drugs and/or photodynamic therapy (PDT) constitute
current treatments targeting pathological vascular tissues in tumors and age-related macular degeneration. Concern
that PDT might induce VEGF and exacerbate the disease has led us to current practice of using anti-VEGF drugs with
PDT simultaneously. However, the underlying molecular mechanisms of these therapies are not well understood.
Methods: We assessed VEGF levels after PDT of normal mouse retinal tissue, using a laser duration that did not
cause obvious tissue damage. To determine the role of PDT-induced VEGF and its downstream signaling, we
intravitreally injected a VEGF inhibitor, VEGFR1 Fc, or a PI3K/Akt inhibitor, LY294002, immediately after PDT. Then,
histological and biochemical changes of the retinal tissue were analyzed by immunohistochemistry and
immunoblot analyses, respectively.
Results: At both the mRNA and protein levels, VEGF was upregulated immediately and transiently after PDT. VEGF
suppression after PDT resulted in apoptotic destruction of the photoreceptor cell layer in only the irradiated area
during PDT. Under these conditions, activation of the anti-apoptotic molecule Akt was suppressed in the irradiated
area, and levels of the pro-apoptotic protein BAX were increased. Intravitreal injection of a PI3K/Akt inhibitor
immediately after PDT increased BAX levels and photoreceptor cell apoptosis.
Conclusion: Cytotoxic stress caused by PDT, at levels that do not cause overt tissue damage, induces VEGF and
activates Akt to rescue the neural tissue, suppressing BAX. Thus, the immediate and transient induction of VEGF
after PDT is neuroprotective.
Keywords: VEGF, PDT, retina, neuroprotection, Akt, BAX
Background
Vascular endothelial growth factor (VEGF) was first
identified as a soluble factor that promotes tumor neo-
vascularization [1]. Targeting VEGF has been a key ther-
apeutic strategy for inducing tumor regression [2]. This
technology has been widely applied in other fields as
well, including treatment of age-related macular degen-
eration (AMD) [3-5]. AMD is a vision-threatening dis-
ease caused by choroidal neovascularization that can
secondarily cause irreversible damage to the neural
retina. The rationale for targeting VEGF in such diseases
is its potential role as a pathogenic factor that promotes
deleterious growth of vascular tissues [6-10]. However,
VEGF is also a physiological factor [11], indispensable
for the maintenance of healthy vessels [12,13] and neu-
rons [14,15]. Since VEGF functions as a double-edged
sword, caution is required in its therapeutic use, to
make sure that its effect on diseased tissue is desirable.
Thus, the physiological roles of VEGF in normal tissue
and disease need to be well understood.
Another therapeutic strategy for vascular suppression
is photodynamic therapy (PDT) [16,17], which involves
the intravenous injection of a photosensitizer, vertepor-
fin, that accumulates in neovascular tissue, which is
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degree of laser irradiation is far too low to cause ther-
mal injury, the activated verteporfin generates reactive
oxygen species, which are cytotoxic and induce transient
thrombosis leading to vessel closure [18]. PDT has been
used in anti-tumor therapy to induce regression of fee-
der vessels [19], and it is now also being used as a treat-
ment for AMD [16,20,21].
A recent study, performed in patients with untreatable
ocular malignancy requiring enucleation, showed induc-
tion of VEGF after PDT [22]. This isolated study
prompted concern that VEGF elevation after PDT could
activate growth of residual neovascular tissue. Therefore,
these two types of vascular suppressive therapies are
sometimes used simultaneously as a combined therapy,
in hopes of obtaining greater vascular regression and a
better visual prognosis [23]. However, the mechanism of
VEGF induction after PDT and its function under these
conditions have not been investigated.
The reason for VEGF’s induction after PDT could be
hypoxia due to normal vessel closure [22], since hypoxia
can induce VEGF via DNA binding of hypoxia-inducible
factors (HIFs) [24]. However, the stress-response element in
the vegf gene [25] may be activated by PDT-induced oxida-
tive stress, not only in choroidal neovascularization (CNV)
but also in surrounding tissues that receive low-level laser
irradiation during PDT. If VEGF is upregulated in response
to PDT-induced stress, it may be an important component
of the stress-activated biological defense system [26]. In this
case, anti-VEGF therapy concomitant with PDT could
harm surrounding retinal tissue, which directly affects visual
function. Therefore, we decided to investigate the expres-
sion response and role of VEGF in the retina after PDT.
In this study, we performed PDT on normal, intact
mouse retina, using a laser level below the damage
threshold for normal tissue, and analyzed VEGF expres-
sion. We also studied the histological consequences of
suppressing VEGF function after PDT, and examined
the activation of a downstream component of the VEGF
signal, Akt, and BAX, a mitochondria-related proapop-
totic molecule inhibited by Akt. The use of normal
retina in this study, instead of an artificial CNV model
induced by high-level laser irradiation, allowed us to
simplify the analyses of the biological defense system in
the normal retina, and also to study histological
changes, since in the CNV model, neural retina has
already been damaged during induction of the model,
thus PDT-induced damage would be difficult to identify.
Methods
Animals and Photodynamic Therapy
All animal experiments described in this study were
conducted in accordance with the ARVO (Association
for Research in Vision and Ophthalmology) Statement
for the Use of Animals in Ophthalmic and Vision
Research.
Six-week-old C57BL/6 mice (Clea, Tokyo, Japan) were
anesthetized with pentobarbital sodium (70 mg/kg body
weight) and immobilized on a stereotactic frame. The
pupils were dilated with a mixed solution of 0.5% tropi-
camide and 0.5% phenylephrine (Mydrin-P
®;S a n t e n ,
Osaka, Japan). Verteporfin (3.0 mg/m
2 body surface
area; Visudyne
®; Novartis, Basel, Switzerland) was
injected into the tail vein as a bolus in a volume of 0.2
ml. Fifteen minutes after the injection, 690-nm laser
light was administered using a diode laser (Visulas 690s;
Carl Zeiss Meditec, Jena, Germany) delivered through a
slit lamp adaptor. The laser spot size was set at 800 μm,
and the exposure of the intact retina was 300 μma w a y
from the optic disc, as confirmed by a micrometer. The
laser power was set at 600 mW/cm
2, and it was deliv-
ered for 42, 20, or 10 seconds, to yield a fluence of 25,
12, or 6 J/cm
2, respectively.
Intravitreous injection of a VEGFR1 Fc fusion protein or
LY294002
Animals received 1-μl intravitreous injections of a
VEGFR1 Fc fusion protein or LY294002 via an UltraMi-
cro-Pump (type UMP2) equipped with a MicroSyringe
Pump Controller (World Precision Instruments, Sara-
sota, FL) [27], immediately after PDT. A mouse
VEGFR1 Fc chimera (R&D Systems) [11] was dissolved
in sterile PBS at 0.5, 1, and 2 μg/μl. This fusion protein
blocks all VEGF isoforms. LY294002 was dissolved in
DMSO at 5 mg/ml and diluted to 10 μMi nP B S .F o r
controls, vehicle, either sterile PBS or PBS with the cor-
responding concentration of DMSO, was injected.
Histological analysis
Sections were prepared using a protocol described else-
where [28]. Briefly, retinal samples were fixed with 4%
paraformaldehyde and prepared for cryosectioning.
Cryosections (9 μm), passing through the optic nerve
and the middle of the PDT spot, were prepared. Sec-
tions obtained from eyes 7 days after PDT were stained
with hematoxylin and eosin, and those obtained 3 days
after PDT were used for TUNEL assays and immunos-
taining. TUNEL staining was performed according to
the manufacturer’s protocol (ApopTag Fluorescein In
Situ Apoptosis Detection Kit; Chemicon, Temecula, CA)
and as previously described [29]. TUNEL-positive cells
were counted and the average number per section was
calculated. To detect pAkt, endogenous peroxidase was
abolished by incubating sections in 3% (wt/vol.) hydro-
gen peroxide in methanol for 20 min. Sections were
then incubated in blocking solution (10% normal bovine
serum in PBS), and then with a rabbit anti-pAkt anti-
body (1:25; Cell Signaling Technology), followed by a
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radish peroxidase complexes (Vectastain Elite ABC Kit).
The reaction product was developed by incubation for
10 min in Tyramide Signal Amplification Solution (Per-
kin Elmer Life Sciences, Boston, MA, USA). Nuclei were
counter-stained with bisbenzimide at a 1:1000 dilution
of a 10 mg/mL stock solution (Hoechst 33258; Sigma).
All the sections were examined using a microscope
equipped with a digital camera (Carl Zeiss, Jena,
Germany).
Real-time (RT)-PCR
Total RNA was isolated from the retina with TRIzol
(Invitrogen, Carlsbad, CA) and reverse-transcribed with
a cDNA synthesis kit (First-Strand; Amersham Bios-
ciences, Inc., Piscataway, NJ), according to the manufac-
turers’ protocols. PCR was performed with TaqMan
®
Fast Universal PCR Master Mix in an Applied Biosys-
tems 7500 Fast real time PCR system (Applied Biosys-
tems, Foster City, CA). The primers were the TaqMan
probes for b-actin and vegf A. The results are presented
as the ratio of the mRNA of vegf to that of an internal
control gene, b-actin.
ELISA
The neural retina or retinal pigment epithelium (RPE)-
choroid complex of each mouse was carefully isolated
and placed into 100 μl of lysis buffer (0.02 M HEPES,
10% glycerol, 10 mM Na4P2O7, 100 μM Na3VO4, 1%
Triton, 100 mM NaF, 4 mM EDTA [pH 8.0]) supple-
mented with protease inhibitors [30]. After sonication,
the lysate was centrifuged at 15,000 rpm for 15 minutes
at 4°C. The protein level of VEGF in the supernatant
was determined with a mouse VEGF ELISA kit (R&D
Systems, Minneapolis, MN), according to the manufac-
turer’s instructions. The tissue concentration was calcu-
lated from a standard curve and corrected for protein
concentration as evaluated by the NanoDrop ND-1000
spectrophotometer (Thermo Fisher Scientific, Waltham,
MA), as previously described [28].
Immunoblot analyses
Isolated retinas were placed into lysis buffer (10 mmol/l
TRIS-HCl [pH 7.6], 100 mmol/l NaCl, 1 mmol/l EDTA,
1% [wt/vol] Triton X-100, and protease inhibitors) as
previously described [31]. Each sample was separated by
SDS-PAGE and electroblotted onto a polyvinylidene
fluoride membrane (Millipore, Bedford, MA, USA).
After being blocked in TNB buffer, the membrane was
incubated at 4°C overnight with a rabbit polyclonal anti-
phospho-Akt antibody (1:1,000; Cell Signaling), anti-
BAX antibody (1:1,000; Cell Signaling), and mouse
monoclonal anti-a-tubulin antibody (1:10,000; Sigma-
Aldrich), respectively. The signals were visualized by
chemiluminescence (ECL Blotting Analysis System;
Amersham, Arlington Heights, IL, USA), measured by
Image J software, and normalized to a-tubulin.
Statistical analyses
All results are expressed as mean ± SD. The values were
assessed for statistical significance (Mann-Whitney test),
and differences were considered significant at P < 0.05.
Results
Defining the conditions for PDT in mice
We first evaluated histological changes in the mouse
retina after PDT of various durations, to define appro-
priate sub-damage threshold irradiation period for our
analysis. We injected verteporfin at 3 mg/m2, and per-
formed low-level laser treatments 300 μma w a yf r o m
the optic disc for 42, 20, or 10 seconds.
In sections of retina obtained 7 days after PDT, the
photoreceptor cell layer was thinned at the site of irra-
diation and showed a loss of photoreceptor cells at the
longest (42-second) PDT duration (Figure 1A). No
obvious thinning was seen in retinal sections treated
with PDT for 20 or 10 seconds (Figure 1B,C). We next
performed TUNEL assays in sections of retina obtained
3 days after PDT. In sections irradiated for 42 seconds,
obvious TUNEL-positive labeling was observed in the
photoreceptor cell layer (Figure 1D,G). Almost no posi-
tive cells were observed after 20 or 10 seconds of PDT
(Figure 1E-G). The changes after PDT were observed
only in the irradiated area. The remainder of the retina
was intact; thus the significance of retinal histological
changes in the irradiated area were well defined by com-
parison with the non-irradiated retina.
On the basis of these preliminary findings, we per-
formed PDT for 20 seconds in the following experi-
ments, since this duration of PDT did not cause obvious
morphological changes in the neural retina.
VEGF induction in the retina after PDT
Next, we analyzed VEGF levels after PDT. mRNA levels
measured by real time (RT)-PCR showed a peak
increase 1.5 hours after PDT that returned to baseline
by 3 days after PDT (Figure 2A). By ELISA, VEGF pro-
tein levels peaked 3 hours after PDT, and also gradually
decreased and returned to baseline by 3 days post-PDT
(Figure 2B). Thus, both VEGF mRNA and protein levels
increased immediately and transiently in the retina after
PDT.
Influence of VEGF inhibition after PDT
To explore the role of increased VEGF after PDT, we
injected a VEGF inhibitor, VEGF receptor 1 Fc chimera
(VEGFR1 Fc) immediately after PDT and analyzed ret-
inal sections 7 days later. Sections of control retinas,
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changes (Figure 3A). However, in sections from PDT
and VEGFR1 Fc-treated retinas, the thickness of the
photoreceptor cell layer was reduced in the irradiated
area, with a dose-dependent increase in severity from
0.5 μg/μlt o2μg/μl (Figure 3B-D,I). We also found a
dose-dependent increase in the number of TUNEL-posi-
tive cells in the ONL, 3 days after the combined PDT
and VEGFR1 Fc treatment (Figure 3E-H,J). These data
show that VEGF inhibition immediately after PDT pro-
motes photoreceptor cell apoptosis.
Influence of VEGF inhibition on Akt and BAX
We next analyzed the influence of VEGF inhibition on
Akt activation in PDT-treated retina. Immunoblot analy-
sis showed that, one day after PDT, levels of phosphory-
lated (i.e., activated) Akt increased in PDT-treated retina
compared with retina with no PDT, under the vehicle
Figure 1 Defining PDT duration for mice. (A-C) Hematoxylin-eosin staining of a retinal section 7 days after PDT. The photoreceptor cell layer
was thin in the area irradiated for 42 seconds using low-level laser light during PDT (A). No obvious changes were observed in retinal sections
exposed to 20 or 10 seconds of laser irradiation (B,C). (D-G) TUNEL (red) and Hoechst (blue) stainings of retinal sections 3 days after PDT. TUNEL-
positive cells were observed in the photoreceptor cell layer in only the irradiated area of retinas exposed to 42 seconds of laser light (D). Few
TUNEL-positive cells were observed in areas exposed to 20 or 10 seconds of laser irradiation (E,F). TUNEL-positive cells in retinal sections were
counted (G). Scale bar, 50 μm. **p < 0.01.
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ing VEGFR1 Fc (2 μg/μl) immediately after PDT, levels
were significantly lower than with vehicle injection after
PDT (Figure 4A,B). In contrast, levels of BAX were sig-
nificantly higher when VEGF inhibition was combined
with PDT, although the level was not changed by PDT
under the vehicle injection condition (Figure 4C,D). In
retinal sections 3 days after PDT, phosphorylated Akt
appeared in the photoreceptor cells of the irradiated
area, but such staining was hardly observed in VEGFR1
Fc (2 μg/μl)-treated retina (Figure 4E).
Influence of Akt inhibition after PDT
We next investigated whether reduced Akt signaling was
involved in apoptosis of photoreceptor cells after PDT.
To do this, we inhibited an upstream component of the
Akt signal, PI3K, by injecting LY294002 (10 μM) into
the retina immediately after PDT. First, we confirmed
that the injection suppressed levels of phosphorylated
and activated Akt 1 day after PDT (Figure 5A,B), and
found that BAX levels increased in the same retina (Fig-
ure 5C,D). Three days after the treatments, TUNEL
assay labeled cells in the laser-irradiated area only when
Figure 2 V E G Fi n d u c t i o ni nr e t i n aa f t e rP D T .( A )vegf mRNA expression in neural retina analyzed by real-time (RT)-PCR. vegf mRNA was
upregulated transiently 1.5 hours after PDT. (B) VEGF protein expression analyzed by ELISA. VEGF protein increased transiently 3 hours after PDT.
*p < 0.05, **p < 0.01.
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injection with PDT (Figure 5E-G). Therefore, Akt activa-
tion after PDT promoted retinal cell survival.
Discussion
Here we demonstrate that the VEGF expression that is
induced in mouse retina after PDT is neuroprotective.
VEGF inhibition suppressed Akt activation and
increased BAX levels in retina, leading to photoreceptor
cell apoptosis after PDT, but only within the irradiated
area. Suppression of Akt activation with a PI3K inhibitor
also increased BAX expression and apoptosis of irra-
diated photoreceptor cells. Thus, VEGF plays a neuro-
protective role, activating Akt, in the stressed retina.
Since inhibition of VEGF induced apoptosis of photore-
ceptor cells in the irradiated area, PDT caused pro-apopto-
tic stress. This stress was compensated for by VEGF
expression in retinas treated with PDT alone. This finding
is consistent with VEGF’s reported role in other neural sys-
tems. For example, brain infarction induces VEGF expres-
sion, and administration of VEGF reduces brain damage
after stroke [15,26,32,33]. Alternatively, transgenic mice
expressing reduced levels of VEGF because of a mutant
VEGF promoter show neurodegeneration similar to amyo-
trophic lateral sclerosis (ALS); this neurodegeneration is
prevented by VEGF treatment [34]. In another knock-in
mouse model, in which the hypoxia response element
sequence in the vegf promoter is deleted, reduced VEGF
expression leads to motor neuron degeneration [14].
The influences of inhibiting VEGF expression after
PDT were not observed outside the irradiated area,
which indicates that this level of VEGF inhibition is not
cytotoxic for non-irradiated and non-stressed retinal
cells. Moreover, the induction of VEGF in the irradiated
retina was immediate and transient, suggesting that
VEGF’s function under these conditions may be
required in a specific time window after stress. We
obtained support for this idea by inhibiting VEGF in
retina 7 days before or after PDT, and finding almost no
apoptotic cells in the irradiated area (Figure 6). There-
fore, VEGF inhibitor injected 7 days before PDT may
not persist and inhibit VEGF’sa c t i o ni nt h er e t i n a
immediately after PDT. On the other hand, the retina
m a yh a v er e c o v e r e df r o mt h es t r e s sw i t h i n7d a y sf r o m
PDT, as we found that VEGF inhibition 7 days after
PDT at this level did not cause photoreceptor cell death.
Figure 3 Influence of VEGF inhibition after PDT. (A-D) Hematoxylin-eosin staining of a retinal section 7 days after PDT with VEGF inhibition.
Damage to the photoreceptor cell layer was obvious when VEGFR1 Fc was injected into the eye immediately after PDT (B-D). (E-H) TUNEL (red)
and Hoechst (blue) stainings of retinal sections 3 days after PDT with VEGF inhibition. TUNEL-positive cells increased when VEGFR1 Fc was
injected after PDT (F-H). The thickness of photoreceptor cell layer in the center of the lesion was measured (I) and the number of TUNEL-positive
cells were counted (J). The effects were dose-dependent. Scale bar, 100 μm. *p < 0.05, **p < 0.01.
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of irradiated photoreceptor neuronal cells, reducing
BAX, an apoptotic Bcl-2 family protein. VEGF’s activa-
tion of Akt is consistent with a previous report showing
that Akt activation occurs downstream of VEGF recep-
tor (VEGFR) 2 signaling [35]. There are reports that
VEGFR 2 signaling [36] and Akt [37] both inhibit the
activation and translocation of BAX to mitochondria.
What we observed, however, was a decrease in BAX
protein levels when the VEGF-Akt pathway was
activated. Recent papers report that Akt phosphorylates
BAX, which shortens its half-life as well as blocking its
translocation [38,39]. A reduced half-life of BAX may
be, at least in part, the mechanism responsible for the
biological defense system induced by PDT. The finding
in this study that phosphorylated Akt is expressed in the
cytoplasm of photoreceptor cells (Figure 4E arrows) sup-
ports this idea.
Cytological changes after PDT have been shown in a
crayfish stretch receptor that consists of a single sensory
Figure 4 Influence of VEGF inhibition on Akt and BAX. (A-D) Immunoblot analyses. One day after PDT with vehicle injection, pAkt levels
increased, but levels were decreased by VEGF inhibition with injection of VEGFR1 Fc (2 μg/μl) into the eye immediately after PDT (A,B). BAX
levels in the retina were not changed by PDT when vehicle was injected, but increased when VEGFR1 Fc (2 μg/μl) was injected immediately
after PDT (C,D). (E) Immunohistochemistry. Three days after PDT, pAkt was observed in photoreceptor cells, in cell bodies and outer segments
(arrows), of the irradiated area of the vehicle-treated retina, but little staining was observed in the VEGFR1 Fc (2 μg/μl)-treated retina. pAkt,
phosphorylated Akt, ONL, outer nuclear layer, OS, outer segment. *p < 0.05, **p < 0.01.
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of some mitochondria, the Golgi apparatus, and endo-
plasmic reticulum cisterns [40]. The changes in the
mitochondria and Golgi apparatus are the first to occur
and persist the longest, and therefore these subcellular
organelles are judged to have the greatest sensitivity to
PDT [41]. Our finding that BAX, an essential molecule
for the mitochondrial apoptotic pathway, increased after
PDT when VEGF was inhibited is consistent with the
histological findings in the crayfish.
PDT is a widespread treatment for AMD, as is anti-
VEGF therapy. The latter is a leading treatment for
Figure 5 Influence of Akt inhibition after PDT. (A-D) Immunoblot analyses. pAkt levels decreased (A,B) and BAX levels increased (C,D) in retina
1 day after a PI3K inhibitor (LY294002, 10 μM) was injected into the eye. (E-G) TUNEL (red) and Hoechst (blue) stainings 3 days after PDT.
LY294002 injection increased the number of TUNEL-positive cells in the irradiated area. pAkt, phosphorylated Akt. Scale bar, 50 μm. *p < 0.05.
Figure 6 TUNEL staining after PDT and VEGF inhibition. (A-H) TUNEL (red) and Hoechst (blue) stainings of retina. Eyes were injected with
VEGFR1 Fc (2 μg/μl) 7 days before PDT, and retinas were fixed 3 days after PDT (A,B,E,F). Or, VEGFR1 Fc (2 μg/μl) was injected 7 days after PDT,
and retinas were fixed 3 days after injection (C,D,G,H). Almost no TUNEL staining is observed in the retina. Scale bar, 100 μm (A-D), 50 μm (E-H).
Suzuki et al. Journal of Neuroinflammation 2011, 8:176
http://www.jneuroinflammation.com/content/8/1/176
Page 8 of 11AMD, but requires repeated treatments and a significant
investment of time on the part of patient and doctor. In
contrast, PDT has a rapid effect. Thus, a recent trial was
undertaken to combine PDT and anti-VEGF therapy, in
order to shut down CNV as quickly as possible. In addi-
tion, the possibility that VEGF might be elevated after
PDT-mediated vascular occlusion because of the result-
ing hypoxia [22] has provided a popular rationale for
such simultaneous combined therapy.
Here, we found that VEGF levels after PDT increased
only transiently in neural retina. Moreover, VEGF is
physiologically secreted by RPE and most probably by
choroidal components, but is not induced and rather
reduced in RPE-choroid complex after PDT (Figure 7).
Because the VEGF inhibition immediately after PDT
also induced apoptosis of RPE as observed in Figure 3,
RPE would be affected by PDT and would required
VEGF’s action to avoid apoptosis. Thus, the production
of VEGF might be influenced by a decrease in bioactiv-
ity of RPE cells. This is consistent with previous data
showing a trend toward reduced density of the chorioca-
pillaris, which is positively regulated by VEGF under
physiological condition, in the irradiated areas of retina
when treated in combination with an anti-VEGF drug in
monkey eyes [42]. Although our current study did not
examine the effects of VEGF blockade on PDT-treated
CNV, overall VEGF levels after PDT may not be ele-
vated as highly as assumed. Our results suggest that the
use of an anti-VEGF drug simultaneously with PDT
might not be a suitable treatment to protect visual func-
tion considering the side effects. Combined therapy may
promote photoreceptor cell death and visual function
impairment, based on our results. Instead, allowing the
tissue to regulate its VEGF level may be more important
for optimizing neuroprotection and retinal function.
Alternatively, adjuvant therapy to increase Akt activation
may be beneficial in clinical applications. In any case,
the molecular mechanisms underlying any treatment
should be considered when establishing a protocol for
combination therapy. Given that PDT can be used to
treat solid organ tumors, such as cancer of the lung or
brain [43], and may cause side effects by damaging
intact tissue, we hope our data will help improve patient
prognosis after PDT treatment in the fields of oncology
as well as ophthalmology.
Conclusions
The immediate and transient induction of VEGF in
response to PDT is neuroprotective and is required for
photoreceptor cell survival, activating Akt which inhibits
BAX. Since VEGF functions as a double-edged sword,
an understanding of its roles in each context is required
to establish better therapeutic protocols leading to better
prognosis.
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